50 results
8-K
EX-99.1
CTIC
CTI BioPharma Corp
7 May 20
CTI BioPharma Reports First Quarter 2020 Financial Results
4:05pm
of the ongoing Phase 3 PACIFICA trial,” said Adam R. Craig, M.D., Ph.D. “Additionally, in response to the global COVID-19 pandemic, as pacritinib has … . With regards to the PACIFICA Phase 3 trial timeline, we anticipate at least a three-month delay to enrollment due to the COVID-19 pandemic.”
First
8-K
EX-99.1
CTIC
CTI BioPharma Corp
6 Aug 20
CTI BioPharma Reports Second Quarter 2020 Financial Results
4:13pm
but the enrollment rate is lower than planned due to the COVID-19 pandemic and we now anticipate at least a six-month delay in the trial. However … for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
Forward
8-K
EX-99.1
CTIC
CTI BioPharma Corp
28 Sep 22
Other Events
4:05pm
in clinical trials caused by the COVID-19 pandemic and risks relating to the conditional approval of VONJO; potential increases in patient morbidity … and/or mortality in clinical trials due to the COVID-19 pandemic; our ability to develop, obtain regulatory approval of and commercialize VONJO for other
8-K
EX-99.1
o7uez fbjpvi
1 Jun 21
CTI BioPharma Reports First Quarter 2021 Financial Results
4:09pm
8-K
EX-99.1
o7vfc
10 Nov 20
CTI BioPharma Reports Third Quarter 2020 Financial Results
4:15pm
8-K
EX-99.1
n0thu5378rz0j81
24 Aug 21
CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors
9:42pm
8-K
EX-99.1
pxb3 1i5jipb
5 Aug 21
CTI BioPharma Reports Second Quarter 2021 Financial Results
4:10pm
8-K
EX-99.1
tgc 1fzlscnmu
17 Mar 21
CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results
4:08pm
8-K
6177k
22 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:38pm
8-K
EX-99.1
w2x5lv5 raollr2x
31 Mar 22
CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results
4:04pm